No connection

Search Results

JAGX vs SXTP

JAGX
Jaguar Health, Inc.
BEARISH
Price
$0.37
Market Cap
$4.6M
Sector
Healthcare
AI Confidence
95%
SXTP
60 Degrees Pharmaceuticals, Inc.
BEARISH
Price
$1.84
Market Cap
$4.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
JAGX
--
SXTP
--
Forward P/E
JAGX
-0.06
SXTP
-0.23
P/B Ratio
JAGX
-0.13
SXTP
-0.35
P/S Ratio
JAGX
0.4
SXTP
3.44
EV/EBITDA
JAGX
-1.12
SXTP
-1.53

Profitability

Gross Margin
JAGX
67.21%
SXTP
44.52%
Operating Margin
JAGX
-631.9%
SXTP
-606.03%
Profit Margin
JAGX
0.0%
SXTP
0.0%
ROE
JAGX
--
SXTP
-200.92%
ROA
JAGX
-61.46%
SXTP
-87.17%

Growth

Revenue Growth
JAGX
-7.8%
SXTP
16.2%
Earnings Growth
JAGX
--
SXTP
--

Financial Health

Debt/Equity
JAGX
--
SXTP
0.05
Current Ratio
JAGX
0.5
SXTP
2.66
Quick Ratio
JAGX
0.07
SXTP
1.77

Dividends

Dividend Yield
JAGX
--
SXTP
--
Payout Ratio
JAGX
0.0%
SXTP
0.0%

AI Verdict

JAGX BEARISH

JAGX exhibits extreme financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.13, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a Quick Ratio of 0.07, suggesting it cannot meet short-term obligations. Despite a positive gross margin, the operating margin is catastrophic at -631.90%, and the stock has collapsed by 92.8% over the last year. The combination of declining revenue and consistent earnings misses points toward a high risk of insolvency.

Strengths
Positive Gross Margin (67.21%)
Low Price-to-Sales ratio (0.40)
Recent reduction in the magnitude of quarterly losses
Risks
Severe liquidity risk (Quick Ratio 0.07)
Negative equity (Price/Book -0.13)
Catastrophic operating losses (-631.90% margin)
SXTP BEARISH

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress. The company exhibits catastrophic profitability metrics, including an operating margin of -606.03% and negative equity (Price/Book of -0.35). While revenue shows modest growth and analysts maintain a speculative 'strong_buy' rating with a high target price, the fundamental data reveals a company in a state of collapse, with a 1-year price decline of 85.4%. The disconnect between the target price of $14.10 and the current price of $1.84 suggests a lack of fundamental support for current analyst projections.

Strengths
Positive YoY revenue growth of 16.20%
Strong Q/Q revenue growth of 31.42%
Low Debt/Equity ratio (0.05)
Risks
Negative shareholder equity (Price/Book -0.35)
Extreme operational cash burn (Operating Margin -606.03%)
Severe earnings misses, most recently -308.6% surprise

Compare Another Pair

JAGX vs SXTP: Head-to-Head Comparison

This page compares Jaguar Health, Inc. (JAGX) and 60 Degrees Pharmaceuticals, Inc. (SXTP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile